11.12.15
In its recent deal with Coty, in which P&G sold off many of its cosmetic and fragrance brands, the giant consumer goods manufacturer held on to its skin care portfolio. With that focus in sight, P&G has now acquired exclusive rights to develop new products with Niagen, a dietary supplement that’s been touted for its anti-aging properties.
The companies announced a joint development agreement earlier this month in which P&G will “identify and develop stable forms” of Niagen for use in “existing and new P&G products.”
Neither P&G nor ChromaDex Corp., the California-based maker of Niagen, has disclosed which products P&G aims to develop with the Vitamin B3 derivative.
The two-year agreement calls for P&G to make an upfront payment to ChromaDex, along with “additional payments based on the achievement of certain milestones.”
The deal allows for ChromaDex to become an exclusive supplier to P&G if stable forms of Niagen can be developed.
The companies announced a joint development agreement earlier this month in which P&G will “identify and develop stable forms” of Niagen for use in “existing and new P&G products.”
Neither P&G nor ChromaDex Corp., the California-based maker of Niagen, has disclosed which products P&G aims to develop with the Vitamin B3 derivative.
The two-year agreement calls for P&G to make an upfront payment to ChromaDex, along with “additional payments based on the achievement of certain milestones.”
The deal allows for ChromaDex to become an exclusive supplier to P&G if stable forms of Niagen can be developed.
